A generation of American children is encountering a new frontier in medicine: weight-loss drugs once reserved for adults are now reaching tens of thousands of the youngest patients, their prescriptions multiplying 310-fold in less than a decade. Researchers at NYU Langone Health have documented this quiet transformation, finding that roughly one in eleven obese children between ages 8 and 11 received a GLP-1 medication by mid-2026 — a response, however imperfect, to a childhood obesity crisis affecting one in five American children. The acceleration raises questions that medicine has not yet f
GLP-1 prescriptions for obese children under 12 surge 310-fold since 2019
Childhood obesity affects approximately 20% of US children, with GLP-1 treatment now reaching over 20,000 children under 12, though access disparities by income level are emerging.